Veradermics (NYSE:MANE – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Sunday.
MANE has been the subject of several other research reports. Leerink Partners upped their price target on Veradermics from $75.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, April 22nd. Jefferies Financial Group lifted their price objective on shares of Veradermics from $138.00 to $182.00 and gave the stock a “buy” rating in a report on Tuesday. Lifesci Capital initiated coverage on shares of Veradermics in a research note on Tuesday, June 16th. They issued an “outperform” rating and a $135.00 target price for the company. Weiss Ratings assumed coverage on shares of Veradermics in a research report on Tuesday, May 26th. They set a “sell (d+)” rating on the stock. Finally, Citigroup boosted their price target on shares of Veradermics from $120.00 to $135.00 and gave the stock a “buy” rating in a report on Monday, May 18th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $135.60.
View Our Latest Analysis on MANE
Veradermics Trading Down 4.2%
Veradermics (NYSE:MANE – Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.76).
About Veradermics
MANE is a global manufacturer and supplier of flavors, fragrances and ingredients for the food, beverage, personal care, household and fine fragrance markets. Headquartered in France, the company develops and produces aromatic solutions that are used by consumer goods companies, food processors, perfumers and formulators seeking sensory impact, taste modulation and olfactory character for their products.
The company’s product portfolio includes savory and sweet flavor systems, beverage concentrates, natural extracts, essential oils, fragrance compounds, cosmetic ingredients and specialty functional solutions such as taste enhancers and odor masking agents.
Recommended Stories
- Five stocks we like better than Veradermics
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Receive News & Ratings for Veradermics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veradermics and related companies with MarketBeat.com's FREE daily email newsletter.
